SCHEMBL21296655

SCHEMBL21296655

COC(=O)c1c(C)c(C(=O)Nc2ccc(F)c(C(F)F)c2)c2n1CCC2

nearest known ligand 0.64

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SLC10A1 Q14973 20/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21296708 0.91 SLC10A1 (0.64) SLC10A1
SCHEMBL21296712 0.91 SLC10A1 (0.65) SLC10A1
SCHEMBL21296620 0.90 SLC10A1 (0.67) SLC10A1
SCHEMBL30396786 0.90 SLC10A1 (0.67) SLC10A1
SCHEMBL21378246 0.90 SLC10A1 (0.60) SLC10A1
SCHEMBL30094991 0.82 SLC10A1 (0.70) SLC10A1
SCHEMBL21809670 0.82 SLC10A1 (0.70) SLC10A1
SCHEMBL21296656 0.81 SLC10A1 (0.60) SLC10A1
SCHEMBL21296659 0.81 SLC10A1 (0.61) SLC10A1
SCHEMBL23224030 0.80 SLC10A1 (0.64) SLC10A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3759109-B1 SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS GILEAD SCIENCES INC (US) 2023-08-30 EP disclosed
US-20230148157-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-05-11 US disclosed
US-20230148157-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-05-11 US disclosed
US-20230148157-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-05-11 US disclosed
CN-111788204-B Substituted pyrrolizine compounds as inhibitors of HBV replication 吉利德科学公司 2023-05-05 CN disclosed
US-11420974-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2022-08-23 US disclosed
US-20210147429-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2021-05-20 US disclosed
US-20210147429-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2021-05-20 US disclosed
EP-3759109-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS GILEAD SCIENCES, INC. (US) 2021-01-06 EP disclosed
US-10836769-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2020-11-17 US disclosed
US-10836769-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2020-11-17 US disclosed
US-20190292187-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2019-09-26 US disclosed
US-20190292187-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2019-09-26 US disclosed
WO-2019165374-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS GILEAD SCIENCES, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147429-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF HMBS, DHFR, HCCS SLC10A1 1948/4885
US-10836769-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS SLC10A1 1948/4885
US-20230148157-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF HMBS, DHFR, HCCS SLC10A1 1948/4885
US-11420974-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS SLC10A1 1948/4885
US-20190292187-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF HMBS, DHFR, HCCS SLC10A1 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.